Multiple lawsuits filed in New Jersey this month claim that the manufacturer of the blood pressure medication Benicar, Daiichi Sankyo Inc., designed the drug in a defective manner and failed to warn consumers that it could cause chronic diarrhea, nausea, malnutrition, dehydration, and weight loss. Benicar is one of the marketed names for the drug olmesartan medoxomil, which is also sold generically and as Azor and Tribenzor. In July, the FDA mandated that the warning labels be changed to include intestinal problems including severe and chronic diarrhea.
[1] Douglass et al. v. Daiichi Sankyo Inc. et al., case number 1:14-cv-01020, Williams et al. v. Daiichi Sankyou Inc. et al., case number 1:14-cv-00863, Rahman et al. v. Daiichi Sankyo et al., case number 1:14-cv-00864 (SDNJ).
[2] FDA Safety Announcement [7-3-2013]
[1] Douglass et al. v. Daiichi Sankyo Inc. et al., case number 1:14-cv-01020, Williams et al. v. Daiichi Sankyou Inc. et al., case number 1:14-cv-00863, Rahman et al. v. Daiichi Sankyo et al., case number 1:14-cv-00864 (SDNJ).
[2] FDA Safety Announcement [7-3-2013]
RSS Feed
